DCTH
BuyPremium GrowerAI neutralDelcath Systems, Inc. · Healthcare · United States · $500M cap · $4.9M/day traded
$14.42 -2.2% · close 23 Oct · scored 24 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Read our full research report on DCTH (Jun 2026), freeAs of 24 Oct 2026, MoatMap's StockRank for Delcath Systems, Inc. (DCTH) is 78/100, ranked against 24,000+ stocks in 35 markets (Quality 74, Value 26, Momentum 73, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Delcath Systems sells HEPZATO KIT, a liver-directed chemotherapy delivery system for metastatic uveal melanoma. Second-quarter 2026 results sent the shares up about 22%, and the stock has hit 52-week highs. The company has repurchased 0.91% of shares. Growth depends on adding treatment centres and on possible label expansion into other liver cancers. It is a single-product medical technology company whose adoption is still early. Its valuation already reflects strong growth expectations.
ABOUT DELCATH SYSTEMS, INC.
Read
Delcath Systems, Inc. is a commercial-stage oncology company focused on developing and commercializing its proprietary Melphalan Hepatic Delivery System (Melphalan/HDS) for treating primary and metastatic cancers of the liver. The company's unique drug-device combination allows for targeted regional chemotherapy, offering a specialized treatment option for liver-dominant cancers with reduced systemic toxicity.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.7M | 2.1M | 37.2M | 85.2M | 215.3% | 95.4M | 106.2M | 132.0M | 24.4% |
| EPS | -1.20 | -2.94 | -0.93 | 0.08 | — | 0.01 | — | — | — |
| Shares | 34.5M | 22.8M | 33.1M | 34.7M | +0.5% | 34.7M | — | — | — |
| Debt | 15.9M | 10.2M | 1.0M | 0.9M | -61.1% | 2.5M | — | — | — |
| Equity | -5.9M | 15.8M | 68.7M | 111.2M | 165.5% | — | — | — | — |
| Op CF | -24.9M | -31.3M | -18.7M | 22.5M | — | 19.6M | — | — | — |
| Inv CF | -0.2M | -19.7M | -1.0M | -26.6M | — | — | — | — | — |
| Fin CF | 10.1M | 51.8M | 39.4M | 15.0M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Swung more than 63% of stocks we rank over the past year (50% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DCTH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DCTH | Delcath Systems, Inc.(you) | $500M | 78 | Buy |
| VREX | Varex Imaging Corporation | $782M | 76 | Buy |
| TCMD | Tactile Systems Technology, Inc. | $536M | 90 | Strong Buy |
| VMD | Viemed Healthcare, Inc. | $373M | 88 | Strong Buy |
| IRMD | IRADIMED CORPORATION | $1.1B | 75 | Buy |
| ELMD | Electromed, Inc. | $219M | 83 | Strong Buy |
| AOTI.L | AOTI, Inc. | $185M | 71 | Buy |
| SGHT | Sight Sciences, Inc. | $495M | 51 | Hold |
| RCEL | AVITA Medical, Inc. | $480M | 50 | Hold |
| IART | Integra LifeSciences Holdings Corporation | $926M | 59 | Hold |
Peer medians: ROE -31.5% · P/E 27.3x · Gross margin 62.6%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.